| Year |
Citation |
Score |
| 2020 |
Dorigo O, Fiset S, MacDonald LD, Bramhecha Y, Hrytsenko O, Dirk B, Rosu GN, Stanford M. DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer. Journal of Clinical Oncology. 38: 6-6. DOI: 10.1200/Jco.2020.38.5_Suppl.6 |
0.344 |
|
| 2020 |
Dorigo O, MacDonald LD, Schindler J, Bramhecha Y, Torrey H, Kaliaperumal V, Hrytsenko O, Dirk B, Patterson K, Stanford M, Fiset S. Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa). Journal of Clinical Oncology. 38: 6075-6075. DOI: 10.1200/Jco.2020.38.15_Suppl.6075 |
0.348 |
|
| 2019 |
Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. PMID 31367043 DOI: 10.1038/S41586-019-1456-0 |
0.315 |
|
| 2019 |
Möckl L, Pedram K, Roy AR, Krishnan V, Gustavsson AK, Dorigo O, Bertozzi CR, Moerner WE. Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx. Developmental Cell. PMID 31105009 DOI: 10.1016/J.Devcel.2019.04.035 |
0.309 |
|
| 2019 |
Malaker SA, Pedram K, Ferracane MJ, Bensing BA, Krishnan V, Pett C, Yu J, Woods EC, Kramer JR, Westerlind U, Dorigo O, Bertozzi CR. The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proceedings of the National Academy of Sciences of the United States of America. PMID 30910957 DOI: 10.1073/Pnas.1813020116 |
0.312 |
|
| 2019 |
Natarajan S, Foreman KM, Soriano MI, Rossen NS, Shehade H, Fregoso DR, Eggold JT, Krishnan V, Dorigo O, Krieg AJ, Heilshorn SC, Sinha S, Fuh KC, Rankin EB. Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Research. PMID 30862717 DOI: 10.1158/0008-5472.Can-18-2616 |
0.353 |
|
| 2019 |
Tanyi JL, Dorigo O, Oza AM, Strauss JF, Pejovic T, Ghamande SA, Ghatage P, Villella JA, Fiset S, MacDonald LD, Hrytsenko O, Stanford M, Newton RC, Leopold L, Rosu GN. DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression. Journal of Clinical Oncology. 37: 5576-5576. DOI: 10.1200/Jco.2019.37.15_Suppl.5576 |
0.334 |
|
| 2019 |
Natarajan S, Foreman K, Soriano M, Shehade H, Fregoso D, Eggold J, Rosen NS, Heilshorn S, Krieg AJ, Krishnan V, Dorigo O, Sinha S, Fuh KC, Rankin EB. Abstract TMIM-081: THE HYPOXIC TUMOR-MESOTHELIAL NICHE PROMOTES OVARIAN CANCER METASTASIS THROUGH COLLAGEN REMODELING Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Tmim-081 |
0.359 |
|
| 2019 |
Krishnan V, Tallapragada S, Schaar B, Chanana A, Rinker-Schaeffer C, Dorigo O. Abstract TMIM-076: OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION THROUGH THE CCL6-CCR1 SIGNALING AXIS Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Tmim-076 |
0.369 |
|
| 2018 |
Gill NK, Ly C, Nyberg KD, Lee L, Qi D, Tofig B, Reis-Sobreiro M, Dorigo O, Rao J, Wiedemeyer R, Karlan B, Lawrenson K, Freeman MR, Damoiseaux R, Rowat AC. A scalable filtration method for high throughput screening based on cell deformability. Lab On a Chip. PMID 30566156 DOI: 10.1039/C8Lc00922H |
0.36 |
|
| 2018 |
Krishnan V, Schaar B, Tallapragada S, Dorigo O. Tumor associated macrophages in gynecologic cancers. Gynecologic Oncology. PMID 29395307 DOI: 10.1016/J.Ygyno.2018.01.014 |
0.31 |
|
| 2018 |
Schaar B, Krishnan V, Tallapragada S, Dorigo O. Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology. 30: 23-30. PMID 29227304 DOI: 10.1097/Gco.0000000000000433 |
0.348 |
|
| 2018 |
Dorigo O, Tanyi JL, Strauss J, Oza AM, Pejovic T, Ghatage P, Villella JA, Fiset S, MacDonald LD, Leopold L, Rosu GN. Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer. Journal of Clinical Oncology. 36: 5510-5510. DOI: 10.1200/Jco.2018.36.15_Suppl.5510 |
0.305 |
|
| 2018 |
Krishnan V, Raju PA, Vierkoetter K, Patel S, Youngyunpipatkul J, Tallapragada S, Schaar B, Folkins AK, Herzenberg LA, Dorigo O. Abstract 5074: Omentum immune microenvironment: Metastatic niche for ovarian cancer Cancer Research. 78: 5074-5074. DOI: 10.1158/1538-7445.Am2018-5074 |
0.35 |
|
| 2017 |
MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget. 8: 84579-84594. PMID 29137450 DOI: 10.18632/Oncotarget.19961 |
0.312 |
|
| 2017 |
He H, Chiu AC, Kanada M, Schaar BT, Krishnan V, Contag CH, Dorigo O. Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28233218 DOI: 10.1007/S11307-017-1061-2 |
0.339 |
|
| 2017 |
Odunsi K, Cristea MC, Dorigo O, Jazaeri AA, Slomovitz BM, Chagin K, Van Winkle E, Kari G, Iyengar M, Norry E, Bartlett-Pandite AN, Amado RG. A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891). Journal of Clinical Oncology. 35: TPS3094-TPS3094. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps3094 |
0.359 |
|
| 2017 |
Krishnan V, Schaar B, Rinker-Schaeffer C, Dorigo O. Abstract TMEM-028: OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Tmem-028 |
0.364 |
|
| 2016 |
Krishnan V, Berek JS, Dorigo O. Immunotherapy in ovarian cancer. Current Problems in Cancer. PMID 28169004 DOI: 10.1016/J.Currproblcancer.2016.11.003 |
0.32 |
|
| 2015 |
Qi D, Kaur Gill N, Santiskulvong C, Sifuentes J, Dorigo O, Rao J, Taylor-Harding B, Ruprecht Wiedemeyer W, Rowat AC. Screening cell mechanotype by parallel microfiltration. Scientific Reports. 5: 17595. PMID 26626154 DOI: 10.1038/Srep17595 |
0.361 |
|
| 2015 |
Chester C, Dorigo O, Berek JS, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. Journal For Immunotherapy of Cancer. 3: 7. PMID 25806106 DOI: 10.1186/S40425-015-0051-7 |
0.338 |
|
| 2015 |
Elvin JA, Bailey M, Carneiro BA, Ali SM, Vergilio J, Palma NA, Chmielecki J, Frampton GM, Lipson D, Stephens P, Miller VA, Johnson ML, Giles FJ, Ross JS, Dorigo O. Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options. Journal of Clinical Oncology. 33: 5602-5602. DOI: 10.1200/Jco.2015.33.15_Suppl.5602 |
0.325 |
|
| 2015 |
Moughon D, He H, Schokrpur S, Jiang Z, Yaqoob M, David J, Iruela-Arispe L, Dorigo O, Wu L. Abstract A48: M2 macrophage inhibition reverses vascular leaks that cause malignant ascites in late-stage epithelial ovarian cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A48 |
0.336 |
|
| 2015 |
He HM, Yu FB, Quake SR, Dorigo O. Abstract 3202: Single cell analysis of ascites macrophages in ovarian cancer Cancer Research. 75: 3202-3202. DOI: 10.1158/1538-7445.Am2015-3202 |
0.376 |
|
| 2015 |
Wiedemeyer W, Qi D, Gill NK, Santiskulvong C, Dorigo O, Rao J, Taylor-Harding B, Rowat AC. Abstract 226: Parallel microfiltration (PMF): A novel method to screen cell mechanotype Cancer Research. 75: 226-226. DOI: 10.1158/1538-7445.Am2015-226 |
0.393 |
|
| 2014 |
Sharma S, Santiskulvong C, Rao J, Gimzewski JK, Dorigo O. The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells. Integrative Biology : Quantitative Biosciences From Nano to Macro. 6: 611-7. PMID 24718685 DOI: 10.1039/C3Ib40246K |
0.338 |
|
| 2013 |
Santiskulvong C, Sharma S, Bentolila L, Rao JY, Gimzewski J, Dorigo O. Abstract 2122: The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells. Cancer Research. 73: 2122-2122. DOI: 10.1158/1538-7445.Am2013-2122 |
0.334 |
|
| 2012 |
Stoll LM, Parvataneni R, Johnson MW, Gui D, Dorigo O, Sullivan P. Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm. Human Pathology. 43: 1339-43. PMID 22534259 DOI: 10.1016/J.Humpath.2011.12.018 |
0.305 |
|
| 2012 |
Sullivan PS, Maresh EL, Seligson DB, Habeeb O, Wadehra M, Goodglick L, Dorigo O. Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 1140-8. PMID 22460811 DOI: 10.1038/Modpathol.2012.64 |
0.329 |
|
| 2012 |
Karam A, Dorigo O. MMPs in ovarian cancer as therapeutic targets. Anti-Cancer Agents in Medicinal Chemistry. 12: 764-72. PMID 22292752 DOI: 10.2174/187152012802650174 |
0.318 |
|
| 2012 |
Sharma S, Santiskulvong C, Bentolila LA, Rao J, Dorigo O, Gimzewski JK. Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 757-66. PMID 22024198 DOI: 10.1016/J.Nano.2011.09.015 |
0.33 |
|
| 2012 |
Santiskulvong C, Eng C, Wang DT, Lung WY, Zabih S, Koya RC, Dorigo O. Abstract 836: Insulin-like growth factor-I receptor (IGF-IR) dowregulation in cisplatin-resistant human ovarian cancer cells Cancer Research. 72: 836-836. DOI: 10.1158/1538-7445.Am2012-836 |
0.333 |
|
| 2012 |
Topka CR, ElMasri WM, Magyar CE, Song M, Dorigo O. Abstract 1862: NY-ESO-1 and clinicopathological features in ovarian cancer Cancer Research. 72: 1862-1862. DOI: 10.1158/1538-7445.Am2012-1862 |
0.345 |
|
| 2011 |
Penner K, Wadehra M, Steinhardt A, Hogue C, Cass I, Walsh C, Holschneider C, Braun J, Dorigo O. Abstract 3157: Expression of progesterone receptor and p4EBP1 as molecular predictors of response to progestin treatment in endometrial adenocarcinoma and complex atypical hyperplasia Cancer Research. 71: 3157-3157. DOI: 10.1158/1538-7445.Am2011-3157 |
0.314 |
|
| 2011 |
Dorigo O, Moughon DL, Masri WE, Lily W. Abstract C183: Inhibition of CSF1 receptor signaling targets tumor associated macrophages in a murine ovarian cancer model. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C183 |
0.383 |
|
| 2010 |
Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, Dorigo O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken, N.J.). 67: 535-44. PMID 20607860 DOI: 10.1002/Cm.20465 |
0.331 |
|
| 2010 |
Kim A, Gabayan V, Dorigo O, Ganz T, Rivera S. Two Mouse Models Illustrate Different Mechanisms of Anemia of Cancer Blood. 116: 2034-2034. DOI: 10.1182/Blood.V116.21.2034.2034 |
0.304 |
|
| 2009 |
Gallaher SD, Gil JS, Dorigo O, Berk AJ. Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector. Journal of Virology. 83: 3249-57. PMID 19158239 DOI: 10.1128/Jvi.01721-08 |
0.764 |
|
| 2006 |
Schwarz J, Schwarz SC, Dorigo O, Stützer A, Wegner F, Labarca C, Deshpande P, Gil JS, Berk AJ, Lester HA. Enhanced expression of hypersensitive alpha4* nAChR in adult mice increases the loss of midbrain dopaminergic neurons. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 935-46. PMID 16675851 DOI: 10.1096/Fj.05-5497Com |
0.708 |
|
| 2005 |
Gil JS, Gallaher SD, Dorigo O, Berk AJ. 890. Development of a Single Vector System for Gene Delivery Via Hybrid Helper Dependent Adenovirus - Epstein-Barr Virus Vector for Long Term Persistance Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.433 |
0.754 |
|
| 2005 |
Gallaher SD, Gil JS, Dorigo O, Berk AJ. 874. Long-Term Transgene Expression In Vivo from a Helper Dependent Adenovirus|[mdash]|Epstein-Barr Virus Hybrid Vector Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.417 |
0.769 |
|
| 2004 |
Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. Journal of Virology. 78: 6556-66. PMID 15163748 DOI: 10.1128/Jvi.78.12.6556-6566.2004 |
0.765 |
|
| 2004 |
Gallaher SD, Gil JS, Dorigo O, Berk AJ. 773. Non-Invasive In Vivo Detection of Episomes Delivered to Mouse Hepatocytes by a Helper Dependent Adenovirus- Epstein-Barr Virus Hybrid Vector System Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.697 |
0.767 |
|
| 2003 |
Berek JS, Dorigo O, Schultes B, Nicodemus C. Specific keynote: immunological therapy for ovarian cancer. Gynecologic Oncology. 88: S105-9; discussion S. PMID 12586097 DOI: 10.1006/Gyno.2002.6695 |
0.3 |
|
| 2002 |
Shawler DL, Bartholomew RM, Garrett MA, Trauger RJ, Dorigo O, Van Beveren C, Marchese A, Ferre F, Duffy C, Carlo DJ, Sherman LA, Gold DP, Sobol RE. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clinical and Experimental Immunology. 129: 99-106. PMID 12100028 DOI: 10.1046/J.1365-2249.2002.01863.X |
0.34 |
|
| 1998 |
Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, Fakhrai H. Combination of transforming growth factor β antisense and interleukin- 2 gene therapy in the murine ovarian teratoma model Gynecologic Oncology. 71: 204-210. PMID 9826461 DOI: 10.1006/Gyno.1998.5151 |
0.331 |
|
| 1998 |
Dorigo O, Turla ST, Lebedeva S, Gjerset RA. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function Journal of Neurosurgery. 88: 535-540. PMID 9488309 DOI: 10.3171/Jns.1998.88.3.0535 |
0.358 |
|
| 1997 |
Dorigo O, Berek JS. Gene therapy for ovarian cancer: Development of novel treatment strategies International Journal of Gynecological Cancer. 7: 1-13. PMID 12795798 DOI: 10.1046/J.1525-1438.1997.00411.X |
0.37 |
|
| 1997 |
Fakhrai H, Shawler DL, Van Beveren C, Lin H, Dorigo O, Solomon MJ, Gjerset RA, Smith L, Bartholomew RM, Boggiano CA, Gold DP, Sobol RE. Construction and characterization of retroviral vectors for interleukin- 2 gene therapy Journal of Immunotherapy. 20: 437-448. PMID 9409449 DOI: 10.1097/00002371-199711000-00003 |
0.331 |
|
| 1996 |
Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy Proceedings of the National Academy of Sciences of the United States of America. 93: 2909-2914. PMID 8610141 DOI: 10.1073/Pnas.93.7.2909 |
0.346 |
|
| 1995 |
Gjerset RA, Fakhrai H, Shawler DL, Turla S, Dorigo O, Grover-Bardwick A, Mercola D, Wen SF, Collins H, Lin H, Garcia MV, Kruse CA, Royston I, Sobol RE. Characterization of a new human glioblastoma cell line that expresses mutant P53 and lacks activation of the PDGF pathway In Vitro Cellular &Amp; Developmental Biology - Animal: Journal of the Society For in Vitro Biology. 31: 207-214. PMID 7757303 DOI: 10.1007/Bf02639435 |
0.362 |
|
| 1995 |
Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, Fakhrai H. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine ct-26 model of colorectal carcinoma Journal of Immunotherapy. 17: 201-208. PMID 7582256 DOI: 10.1097/00002371-199505000-00002 |
0.31 |
|
| 1995 |
Sobol R, Dorigo O, Shawler D, Lin H, Royston I, Fakhrai H. Immuno-gene therapy of rat glioma with TGF-β2 antisense and IL-2 gene modified tumor cells European Journal of Cancer. 31: S20. DOI: 10.1016/0959-8049(95)99891-3 |
0.323 |
|
| Show low-probability matches. |